2007 FDA drug approvals: a year of flux | PDF (401 KB)

p107 | doi:10.1038/nrd2514

Anticancer drugs: Reversing resistance | PDF (294 KB)

p119 | doi:10.1038/nrd2525

Antivirals: Helping hand for HIV | PDF (221 KB)

p120 | doi:10.1038/nrd2523

Anticancer drugs: Redesigning kinase inhibitors | PDF (222 KB)

p120 | doi:10.1038/nrd2524

High-content screening: Integrating information | PDF (162 KB)

p121 | doi:10.1038/nrd2522

Chemogenomics: A change of tactic | PDF (282 KB)

p122 | doi:10.1038/nrd2521

Derive and conquer: sourcing and differentiating stem cells for therapeutic applications

Irina Klimanskaya, Nadia Rosenthal & Robert Lanza

p131 | doi:10.1038/nrd2403

The success of stem-cell-based therapies depends on finding reliable sources of multipotent and pluripotent cells, and the ability to generate desired derivatives. Here, the authors discuss problems associated with the sourcing of human embyonic stem cells and discuss the current status of stem-cell differentiation technology.

• Abstract
• Full Text
• PDF (1,519 KB)

Is raising HDL a futile strategy for atheroprotection?

Tisha Joy & Robert A. Hegele

p143 | doi:10.1038/nrd2489

Raising high-density lipoprotein cholesterol (HDL-C) levels has attracted considerable interest as an approach for the treatment of cardiovascular disease. However, the failure of the HDL-raising investigational drug torcetrapib in clinical trials has led to significant doubts about the potential of this strategy. This article considers possible reasons for the failure of torcetrapib, and discusses alternative agents and strategies that might effectively, and safely, raise HDL-C.

• Abstract
• Full Text
• PDF (452 KB)

The nitrate–nitrite–nitric oxide pathway in physiology and therapeutics

Jon O. Lundberg, Eddie Weitzberg & Mark T. Gladwin

p156 | doi:10.1038/nrd2466

The supposedly inert end products of endogenous nitric oxide (NO) metabolism — nitrate and nitrite — have recently been shown to be an important alternative source of NO, complementing the classical NO-synthase pathway. Lundberg and colleagues discuss the emerging role of the nitrate–nitrite–NO pathway, highlighting the therapeutic potential of nitrate and nitrite in various disorders, including myocardial infarction, stroke, systemic and pulmonary hypertension, and gastric ulceration.

• Abstract
• Full Text
• PDF (2,242 KB)

Carbonic anhydrases: novel therapeutic applications for inhibitors and activators

Claudiu T. Supuran

p168 | doi:10.1038/nrd2467

Carbonic anhydrases (CAs) are a large family of ubiquitous metalloenzymes that are involved in many physiological and pathological processes. Traditionally, CA inhibition has been clinically applied in the development of diuretic and antiglaucoma agents. Supuran discusses the emerging potential for inhibitors or activators of CAs to treat a wide range of other disorders, including obesity, cancer, osteoporosis, bacterial and fungal infections, as well as Alzheimer's disease.

• Abstract
• Full Text
• PDF (1,227 KB)

From industry to academia

p183 | doi:10.1038/nrd2513

• Abstract
• Full Text
• PDF (193 KB)